We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Fucose Metabolism Linked to Tendency of Melanomas to Metastasize

By LabMedica International staff writers
Posted on 20 Dec 2015
A recent paper linked disruptions in the metabolism of the sugar L-fucose to the tendency of melanoma cells to break away from the primary skin tumor and metastasize to other organs in the body.

Investigators at Sanford Burnham Prebys Medical Discovery Institute (La Jolla, CA, USA) have been studying the activity of an enzyme called activating transcription factor 2 (ATF2), which controls the expression of a number of proteins and has been implicated in the development of melanoma and other cancers.

They reported in the December 8, 2015, issue of the journal Science Signaling that activation of ATF2 by the kinase (an enzyme that catalyzes the transfer of phosphate groups) PKC-epsilon, which was more prevalent in advanced-stage melanomas than in primary melanocytes or early-stage tumors, promoted the metastatic behavior of melanoma cells in culture and in mice. More...
The effect of ATF2 on melanoma cells was shown to be due to its inhibition of the expression of the gene encoding the enzyme fucokinase (FUK), which promotes global protein fucosylation (addition of fucose sugar units).

Supplementing drinking water with dietary fucose suppressed the growth and metastasis of melanoma in mice, likely by promoting protein fucosylation, which enhanced cell adhesion and reduced cell migration.

"To our surprise, one of the genes found to be regulated by ATF2 was fucokinase (FUK), which controls the ability of cells to process the dietary sugar, L-fucose, into a form that is useable for the modification (fucosylation) of proteins, many of which are on the cell surface," said senior author Dr. Ze’ev Ronai, scientific director of the Sanford Burnham Prebys Medical Discovery Institute. "Our findings offer new, unprecedented detail into the sugar’s role in cancer. We found that by tampering with L-fucose metabolism, we could inhibit melanoma tumor metastasis. Not only were the tumors affected but also their microenvironment—the cells surrounding the tumor that play a critical role in sustaining the cancer—making the discovery even more impactful."

Related Links:

Sanford Burnham Prebys Medical Discovery Institute



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
Automated Clinical Chemistry Analyzer
Envoy 500+
All-in-One Molecular System
AIO M160
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Graphical abstract (Pola, I., Akinyemi, T., Tan, K. et al. Nature Communications(2026). https://doi.org/10.1038/s41467-026-74971-4)

Blood Biomarker Study Reveals Population-Specific Differences in Alzheimer’s Disease

Blood-based biomarkers are emerging as tools for detecting Alzheimer’s disease–related changes without relying on advanced brain imaging or cerebrospinal fluid (CSF) analysis. However, much of the foundational... Read more

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Blood Test for Lung Cancer Screening Receives FDA Breakthrough Device Designation

Lung cancer remains the leading cause of cancer death in the United States, yet only about 18% of people eligible for screening undergo low-dose computed tomography, the current guideline-recommended method.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.